UK's ImmuPharma interim net loss widens on derivative finance loss
UK's ImmuPharma interim net loss widens on derivative finance loss
Overview
UK drug developer's interim net loss widened to £4.7 mln on derivative finance loss
Operating loss for the half-year narrowed slightly to £1.1 mln from £1.2 mln
Company raised £6.47 mln in April to fund Kapiglucagon and P140 development
Outlook
Company aims to secure a commercial deal for P140 in 2026
ImmuPharma progressing Kapiglucagon towards IND-enabling and first-in-human clinical studies
Company expects cash runway to at least the second half of 2028 after recent fundraising
Result Drivers
DERIVATIVE FINANCE LOSS - Net loss widened mainly due to a £3.36 mln finance loss from the revaluation of a derivative financial asset linked to the fundraising agreement
Company press release: ID:nRSO7134Ua
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Net Loss |
| GBP 4.70 mln |
|
Reuters Recommended Reads
Sept 14 - Definium's LSD-based anxiety, depression drug scores another trial win
Sept 14 - BioNTech says lung cancer drug candidate prolonged lives in trial
Sept 14 - Contineum, J&J's depression drug fails to meet mid-stage trial goal
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)